









Markets
/
Stocks
/
nasdaq-prqr
/

ProQR Therapeutics NV

PRQR

2.190USD

+0.130+6.31%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

235.89MMarket Cap

LossP/E TTM



ProQR Therapeutics NV

2.190

+0.130+6.31%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

91 / 506

Overall Ranking

196 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

9.000

Target Price

+336.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 363.50% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 18.88M.

Fairly Valued

The company’s latest PE is -5.40, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 61.04M shares, decreasing 9.02% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 750.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 7.66, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 3.37M, representing a year-over-year decrease of 44.08%, while its net profit experienced a year-over-year decrease of 311.23%.

Score

Industry at a Glance

Previous score

7.66

Change



Financials

8.08

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.44

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.21

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -5.08, which is -40.27% below the recent high of -3.03 and -19.10% above the recent low of -6.05.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 91/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for ProQR Therapeutics NV is 9.00, with a high of 14.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

9.000

Target Price

+336.89%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

ProQR Therapeutics NV

PRQR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.46, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 2.40 and the support level at 1.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.46

Change

0.35

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.056

Neutral

RSI(14)

50.460

Neutral

STOCH(KDJ)(9,3,3)

34.993

Buy

ATR(14)

0.162

High Vlolatility

CCI(14)

-48.698

Neutral

Williams %R

52.551

Neutral

TRIX(12,20)

0.035

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.083

Buy

MA10

2.197

Sell

MA20

2.232

Sell

MA50

2.197

Sell

MA100

2.010

Buy

MA200

2.094

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 57.95%, representing a quarter-over-quarter decrease of 1.81%. The largest institutional shareholder is Steven Cohen, holding a total of 750.00K shares, representing 0.71% of shares outstanding, with 49.77% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Eli Lilly and Company

16.90M

+26.35%

Van Herk Investments

11.50M

+0.35%

Adage Capital Management, L.P.

8.10M

-15.62%

Privium Fund Management BV

4.99M

Affinity Asset Advisors LLC

3.28M

+16.27%

Morgan Stanley & Co. LLC

1.36M

+193.96%

Sio Capital Management, LLC

2.05M

abrdn Inc.

1.85M

Kynam Capital Management LP

1.75M

Dafna Capital Management, LLC

1.57M

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.06, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.